2026 年 10 月，世达公布 55 人合伙人晋升名单，同月牵头希音港股上市的杜枢转投威嘉。晋升与出走，能用同一条逻辑解释：人在哪，取决于最复杂的那一段落在哪个法域。 / In October 2026, Skadden announced its largest-ever partner class while Du Shu, who led SHEIN’s Hong Kong IPO, left for Weil. Both moves answer to one logic: where a firm places people tracks where the hardest part of the work falls, by jurisdiction.
只做争议解决的昆鹰，如何在中国内地站住十年：三类对手、一个由规矩换来的位置，和这条路要付的账单。 / How a litigation-only firm built a decade in mainland China: three kinds of adversaries, a position bought with a rule, and the bill that comes with it.
2026 年 10 月，恒瑞把一款 GLP-1 新药的境外权益授给诺和诺德，首付款 3 亿美元。这是盛德今年在中国接的第三笔同类交易；三笔都由杨晨承办，她 2007 年建起该所中国生命科学业务。 / In October 2026, Hengrui licensed a GLP-1 drug’s overseas rights to Novo Nordisk for a $300 million upfront payment. It is the third such China outbound deal Sidley has taken this year; all three were led by Chen Yang, who built the firm’s China life sciences practice in 2007.
